- This event has passed.
Continuous safety information of RCT with blinded treatment information: Presentation to the ASA Biopharmaceutical Section Safety Working Group, Q1 2025
January 21
Greg Ball, PhD, of ASAP Process Consulting joins Patrick Schnell, Executive Medical Director and Global Product Safety Lead at BeiGene, to present “Continuous safety information of RCT with blinded treatment information” to the quarterly meeting of ASA’s Biopharmaceutical Section, on January 21, 2025. Greg and Patrick are joined from other industry key opinion leaders from Novartis, Merck, AbbVie, UCB, Boehringer Ingelheim, and Moderna to discuss other important developments in the field of quantitative methods and tools for safety monitoring in clinical trials:
- Safety Signal Exploration using BDRIBS (Merck, AbbVie)
- A Bayesian method for safety signal detection in ongoing blinded randomized controlled trials (UCB)
- An open-source modular approach to Safety Visualization and Analysis (Boehringer Ingelheim)
- Meta-analysis of blinded and unblinded studies (Moderna)
- Quantitative Safety Monitoring in Clinical Trials for infrequent events (Novartis)